{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T16:01:48Z","timestamp":1772121708615,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T00:00:00Z","timestamp":1554422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005624","name":"PATH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline Biologicals SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.vaccine.2019.03.033","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T09:43:51Z","timestamp":1554716631000},"page":"2586-2599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines \u2013 A phase II, randomised, observer-blind study in Gambian infants"],"prefix":"10.1016","volume":"37","author":[{"given":"Aderonke","family":"Odutola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin O.C.","family":"Ota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Antonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezra O.","family":"Ogundare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yauba","family":"Saidu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4287-3577","authenticated-orcid":false,"given":"Patrick K.","family":"Owiafe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archibald","family":"Worwui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8802-2946","authenticated-orcid":false,"given":"Olubukola T.","family":"Idoko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olumuyiwa","family":"Owolabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Kampmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian M.","family":"Greenwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0697-6149","authenticated-orcid":false,"given":"Mark","family":"Alderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magali","family":"Traskine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristien","family":"Swinnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Verlant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Dobbelaere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorota","family":"Borys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.03.033_b0005","unstructured":"Centers for Disease Control. Global pneumococcal disease and vaccine; 2017. Available at: https:\/\/www.cdc.gov\/pneumococcal\/global.html [accessed June 15, 2018]."},{"key":"10.1016\/j.vaccine.2019.03.033_b0010","first-page":"129","article-title":"Pneumococcal vaccines. WHO position paper \u2013 2012","volume":"14","author":"World Health Organization","year":"2012","journal-title":"Week Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2019.03.033_b0015","doi-asserted-by":"crossref","first-page":"e1000348","DOI":"10.1371\/journal.pmed.1000348","article-title":"Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project","volume":"7","author":"Johnson","year":"2010","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2019.03.033_b0020","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/648593","article-title":"Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine","volume":"201","author":"Pilishvili","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.03.033_b0025","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa022823","article-title":"Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine","volume":"348","author":"Whitney","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.03.033_b0030","doi-asserted-by":"crossref","first-page":"e0166736","DOI":"10.1371\/journal.pone.0166736","article-title":"Impact and effectiveness of 10 and 13-valent pneumococcal conjugate vaccines on hospitalization and mortality in children aged less than 5 years in latin american countries: a systematic review","volume":"11","author":"de Oliveira","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.03.033_b0035","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1016\/j.vaccine.2016.03.107","article-title":"Status of research and development of pediatric vaccines for Streptococcus pneumoniae","volume":"34","author":"Alderson","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.03.033_b0040","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1586\/erv.12.5","article-title":"Issues and challenges in the development of pneumococcal protein vaccines","volume":"11","author":"Ginsburg","year":"2012","journal-title":"Expert Rev Vacc"},{"key":"10.1016\/j.vaccine.2019.03.033_b0045","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1016\/j.vaccine.2012.10.080","article-title":"Safety and immunogenicity of a pneumococcal histidine triad protein D vaccine candidate in adults","volume":"30","author":"Seiberling","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.03.033_b0050","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.vaccine.2012.11.005","article-title":"Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults","volume":"31","author":"Kamtchoua","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.03.033_b0055","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.1016\/j.vaccine.2014.02.052","article-title":"Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: a phase I\/II randomized clinical study","volume":"32","author":"Leroux-Roels","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.03.033_b0060","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.vaccine.2014.03.066","article-title":"Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: a phase II randomized clinical trial","volume":"32","author":"Prymula","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.03.033_b0065","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1016\/j.vaccine.2017.07.008","article-title":"Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: Results from a randomized phase II study in infants","volume":"35","author":"Prymula","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.03.033_b0070","unstructured":"World Health Organization. Table 1: Summary of WHO position papers \u2013 recommendations for routine immunization (updated: March 2017); 2017. Available at: http:\/\/www.who.int\/immunization\/policy\/Immunization_routine_table1.pdf [accessed August 8, 2018]."},{"key":"10.1016\/j.vaccine.2019.03.033_b0075","unstructured":"World Health Organization. Table 2: Summary of WHO position papers \u2013 recommended routine immunizations for children (updated March 2017); 2017. Available at: http:\/\/www.who.int\/immunization\/policy\/Immunization_routine_table2.pdf [accessed August 8, 2018]."},{"key":"10.1016\/j.vaccine.2019.03.033_b0080","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.vaccine.2017.03.071","article-title":"Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: a phase 2, randomized, controlled, observer-blind study","volume":"35","author":"Odutola","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.03.033_b0085","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/21645515.2015.1111496","article-title":"Reactogenicity, safety and immunogenicity of a protein-based pneumococcal vaccine in Gambian children aged 2\u20134 years: a phase II randomized study","volume":"12","author":"Odutola","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.03.033_b0090","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1128\/CVI.00289-09","article-title":"Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines","volume":"17","author":"Poolman","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2019.03.033_b0095","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1128\/cdli.4.4.415-422.1997","article-title":"Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells","volume":"4","author":"Romero-Steiner","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2019.03.033_b0100","unstructured":"World Health Organization. Guidelines for WHO\/EPI collaborative studies on poliomyelitis. Standard procedure for determining immunity to poliovirus using the microneutralisation test (WHO\/EPI\/GEN\/93.9); 1993."},{"key":"10.1016\/j.vaccine.2019.03.033_b0105","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-2600(14)70060-8","article-title":"Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study","volume":"2","author":"Domingues","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2019.03.033_b0110","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0140-6736(12)61854-6","article-title":"Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial","volume":"381","author":"Palmu","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.03.033_b0115","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S2213-2600(14)70139-0","article-title":"Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial","volume":"2","author":"Palmu","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2019.03.033_b0120","doi-asserted-by":"crossref","first-page":"e1001657","DOI":"10.1371\/journal.pmed.1001657","article-title":"Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial","volume":"11","author":"Tregnaghi","year":"2014","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2019.03.033_b0125","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1186\/1471-2458-11-882","article-title":"Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial","volume":"11","author":"Dicko","year":"2011","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2019.03.033_b0130","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1097\/INF.0000000000001518","article-title":"Immunogenicity and safety of 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) administered to children with sickle cell disease between 8 weeks and 2 years of age: a phase III, open, controlled study","volume":"36","author":"Sirima","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2019.03.033_b0135","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1097\/INF.0b013e318199f8ef","article-title":"Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine","volume":"28","author":"Vesikari","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2019.03.033_b0140","unstructured":"IVAC. Pneumococcal conjugate vaccine (PCV) product assessment. April 2017; 2017. Available at: https:\/\/www.jhsph.edu\/research\/centers-and-institutes\/ivac\/resources\/pcv-product-assessment-april-25-2017.pdf [accessed August 14, 2017]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1930355X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1930355X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:31:37Z","timestamp":1759401097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1930355X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":28,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0264410X1930355X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.03.033","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735539584.793573980","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines \u2013 A phase II, randomised, observer-blind study in Gambian infants","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.03.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}